<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epcor-mono-3y-rrlbcl-cheah">
    <meta name="study:title" content="PF920 - Sustained remission in relapsed or refractory diffuse large B-cell lymphoma with Epcoritamab monotherapy: EPCORE NHL-1 3-Y results and novel subgroup analyses in patients with complete response at 2 Y">
    <meta name="study:fileName" content="Abstracts/EPCOR-MONO-3Y-RRLBCL-CHEAH.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Epcoritamab,Bispecific antibodies">

    <title>PF920: Epcoritamab Monotherapy in R/R LBCL (3-Y Results) (Cheah) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF920 - Epcoritamab Monotherapy in R/R LBCL: EPCORE NHL-1 3-Year Follow-Up</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=157)</h4>
                    <p>R/R CD20+ LBCL Pts (≥2 prior LOT). 3-yr f/u of EPCORE NHL-1; outcomes in pts with CR at 2y.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Epcoritamab Monotherapy)</h4>
                    <p>48mg SC (step-up C1; QW C1-3; Q2W C4-9; Q4W C≥10) until PD or unacceptable toxicity.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (3-yr Follow-up, N=157)</h4>
                    <p>ORR 59%, CR 41%. mDOR 20.8mo, mOS 18.5mo. Pts in CR at 2y (n=32): 97% OS at 36mo.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Manageable long-term safety (CRS 51%). Epcoritamab shows potential for cure in some 3L+ R/R LBCL pts.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF920 - Sustained remission in relapsed or refractory diffuse large B-cell lymphoma with Epcoritamab monotherapy: EPCORE NHL-1 3-Y results and novel subgroup analyses in patients with complete response at 2 Y</h1>
            <p class="abstract-sub-header">Chan Y. Cheah, Yasmin H. Karimi, Julie M. Vose, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF920 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Depth and duration of complete response (CR) correlate with long-term outcomes in large B-cell lymphoma (LBCL).</li>
                        <li>Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, showed deep, durable responses and manageable safety in pts with R/R LBCL in the pivotal phase 2 EPCORE® NHL-1 trial (NCT03625037).</li>
                        <li>This report presents 3-year follow-up results and a post hoc analysis of pts remaining in CR at 2 years after starting treatment.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Trial: EPCORE NHL-1 (Phase 2, NCT03625037).</li>
                        <li>Patients (N=157): R/R CD20+ LBCL, ≥2 prior lines of therapy (LOT).</li>
                        <li>Treatment Regimen: Epcoritamab monotherapy SC in 28-day cycles (C).
                            <ul class="list-circle list-inside ml-4">
                                <li>C1: Step-up doses (0.16mg, 0.8mg), then 48mg full dose.</li>
                                <li>C1-3: QW dosing.</li>
                                <li>C4-9: Q2W dosing.</li>
                                <li>C≥10: Q4W dosing.</li>
                            </ul>
                        </li>
                        <li>Treatment Duration: Until progressive disease (PD) or unacceptable toxicity.</li>
                        <li>Primary Endpoint: Overall Response Rate (ORR) by Lugano criteria (investigator assessed for long-term outcomes).</li>
                        <li>Data Cutoff: May 3, 2024 (median follow-up: 37.1 months).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">EPCORE NHL-1: Epcoritamab Monotherapy Regimen & Follow-Up</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Pts (N=157)</strong>
                            <span>R/R CD20+ LBCL, ≥2 prior LOT</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Epcoritamab Monotherapy (28-day cycles)</strong>
                                <span>C1: Step-up (0.16mg, 0.8mg) then 48mg QW</span>
                                <span>C2-3: 48mg QW</span>
                                <span>C4-9: 48mg Q2W</span>
                                <span>C≥10: 48mg Q4W</span>
                                <span>(Until PD or unacceptable toxicity)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Primary Endpoint: ORR (Lugano)</span>
                           <span>Long-term: DOR, Duration of CR, PFS, OS</span>
                           <span>Safety (TEAEs, CRS, ICANS)</span>
                           <span>Subgroup Analysis: Pts in CR at 2 years</span>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (Pts in CR at 2 Years, n=32)</h2>
                    <p class="text-sm mb-1">Of 65 pts who achieved CR, 49% (32/65) remained in CR at 2 years.</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 63 years.</li>
                        <li>Male: 47%.</li>
                        <li>Ann Arbor Stage III/IV: 81%.</li>
                        <li>Prior CAR-T Therapy: 38%.</li>
                        <li>Refractory to ≥2 Prior LOT: 66%.</li>
                    </ul>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median Follow-up: 37.1 months)</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Overall Population (N=157):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Overall Response Rate (ORR): 59% (92/157).</li>
                        <li>Complete Response (CR): 41% (65/157).</li>
                        <li>Median Duration of Response (mDOR): 20.8 months (95% CI, 13.0-32.0).</li>
                        <li>Median Duration of CR (mDoCR): 36.1 months (95% CI, 20.1-Not Reached [NR]).</li>
                        <li>Median Progression-Free Survival (mPFS): 4.2 months (95% CI, 2.8-5.5).</li>
                        <li>Median Overall Survival (mOS): 18.5 months (95% CI, 11.7-27.7).</li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">All Patients with CR (n=65):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>mPFS: 37.3 months (95% CI, 26.0-NR).</li>
                        <li>mOS: NR (95% CI, 36.4-NR).</li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">Patients in CR at 2 Years (n=32):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>At 36 months: 96% were progression-free and 97% were alive.</li>
                    </ul>
                     <div class="chart-container my-4">
                        <svg id="epcorSurvivalChart" width="400" height="300"></svg>
                        <div id="epcorSurvivalLegend" class="legend"></div>
                    </div>

                    <p class="text-sm font-semibold mt-3 mb-1">Treatment Discontinuation & Management:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>138 pts (88%) discontinued tx (58% PD, 4% transplant).</li>
                        <li>32 pts with CR discontinued epcoritamab for reasons other than PD/death (median tx duration 13.2 mo; median time in CR post-discontinuation 9.6 mo for 17 pts with scans).</li>
                        <li>19 pts (12%) remained on epcoritamab at data cutoff.</li>
                        <li>15 CR pts had temporary tx pause >6 wks (median 70.5 d); all maintained CR upon reinitiation.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=157)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Safety profile consistent with previous reports.</li>
                        <li><strong>Most Common TEAEs (any grade):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Cytokine Release Syndrome (CRS): 51%</li>
                                <li>Fatigue: 25%</li>
                                <li>Pyrexia: 25%</li>
                            </ul>
                        </li>
                        <li>Incidence and severity of CRS and ICANS were unchanged from previous reports.</li>
                        <li>Serious infections: 31%.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>At 3-year follow-up, epcoritamab monotherapy demonstrated long-term disease remission and the potential for cure in some patients with 3L+ R/R LBCL.</li>
                <li>Patients who achieved a CR, particularly those remaining in CR at 2 years, had excellent long-term PFS and OS.</li>
                <li>The long-term safety profile was consistent with the established safety profile of epcoritamab, with manageable TEAEs.</li>
                <li>Temporary treatment interruptions for over 6 weeks did not compromise CR in responding patients.</li>
                <li>Additional data will be presented to further characterize pts with R/R LBCL who achieved long-term remission.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>2L, Second Line; 3L+, Third Line or Later; ASCO, American Society of Clinical Oncology; C, Cycle; CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CI, Confidence Interval; CR, Complete Response; CRS, Cytokine Release Syndrome; DoCR, Duration of Complete Response; DOR, Duration of Response; Epcor, Epcoritamab; F/U, Follow-up; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; IQR, Interquartile Range; LBCL, Large B-Cell Lymphoma; LOT, Lines of Therapy; m, Median; mo, Months; NR, Not Reached; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PFS, Progression-Free Survival; Pt(s), Patient(s); QW, Once Weekly; Q2W, Once Every 2 Weeks; Q4W, Once Every 4 Weeks; R/R, Relapsed or Refractory; SC, Subcutaneous; TEAE, Treatment-Emergent Adverse Event; Tx, Treatment; y, Years.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Cheah CY, Karimi YH, Vose JM, et al. Sustained remission in relapsed or refractory diffuse large B-cell lymphoma with Epcoritamab monotherapy: EPCORE NHL-1 3-Y results and novel subgroup analyses in patients with complete response at 2 Y. Abstract #PF920 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF920 | Abstract Release: 05/22/2025 | Presentation: 06/13/2025</p>
            <p class="text-xs italic mt-1">© 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting. All rights reserved.</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
        function drawEpcorSurvivalChart(containerId, legendContainerId) {
            const chartTitle = "Key Survival Outcomes with Epcoritamab (Median Follow-up: 37.1 mo)";
            const NR_Placeholder_Months = 40; // Using a value slightly above the highest concrete median for visualization
            
            const chartData = [
                { group: "Overall (N=157)", mDOR: 20.8, mDoCR: 36.1, mPFS: 4.2, mOS: 18.5 },
                { group: "All CR Pts (n=65)", mPFS: 37.3, mOS: NR_Placeholder_Months } // mOS is NR
            ];
            // Pts in CR at 2y (n=32): 96% PFS & 97% OS at 36mo - this is a rate, not a median, harder to directly compare in same bar chart.
            // We will represent this as text or a separate small chart if needed. For now, focusing on medians.

            const subgroups = ["mDOR", "mDoCR", "mPFS", "mOS"];
            const displayLabels = {
                "mDOR": "mDOR",
                "mDoCR": "mDoCR",
                "mPFS": "mPFS",
                "mOS": "mOS"
            };


            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);
            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 400;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 300);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 60, right: 20, bottom: 70, left: 60 }; // Increased bottom for group labels
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);
            const groups = chartData.map(d => d.group);
            
            const xScaleGroups = d3.scaleBand().domain(groups).range([0, chartWidth]).padding(0.3);
            const xScaleSubgroups = d3.scaleBand().domain(subgroups).range([0, xScaleGroups.bandwidth()]).padding(0.05);
            
            // Determine max Y value, considering NR_Placeholder
            let maxYValue = 0;
            chartData.forEach(d => {
                subgroups.forEach(sg => {
                    if (d[sg] && d[sg] > maxYValue) maxYValue = d[sg];
                });
            });
            maxYValue = Math.max(maxYValue, NR_Placeholder_Months);


            const yScale = d3.scaleLinear().domain([0, maxYValue * 1.1]).range([chartHeight, 0]);

            const color = d3.scaleOrdinal()
                .domain(subgroups)
                .range(["var(--sobi-teal)", "var(--sobi-dark-teal)", "var(--sobi-orange)", "var(--sobi-dark-orange)"]);

            g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScaleGroups))
                .selectAll("text").attr("class", "axis-text").style("font-size", "9px").attr("transform", "rotate(-10) translate(-5,0)").style("text-anchor", "end");
            
            g.append("g").call(d3.axisLeft(yScale).ticks(6).tickFormat(d => (d === NR_Placeholder_Months && chartData.some(cd => cd.mOS === NR_Placeholder_Months)) ? "NR" : d.toFixed(0)))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
            
            g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 15).attr("x", 0 - (chartHeight / 2))
                .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Median Duration (Months)");

            g.append("g").attr("class", "grid").call(d3.axisLeft(yScale).ticks(6).tickSize(-chartWidth).tickFormat(""))
                .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

            const groupBars = g.selectAll(".group-bar").data(chartData).enter().append("g")
                .attr("class", "group-bar").attr("transform", d => `translate(${xScaleGroups(d.group)},0)`);

            groupBars.selectAll("rect")
                .data(d => subgroups.filter(sg => d[sg] !== undefined).map(key => ({ key: key, value: d[key] })))
                .enter().append("rect")
                .attr("x", d => xScaleSubgroups(d.key)).attr("y", d => yScale(d.value))
                .attr("width", xScaleSubgroups.bandwidth()).attr("height", d => chartHeight - yScale(d.value))
                .attr("fill", d => color(d.key)).attr("rx", 2).attr("ry", 2);

            groupBars.selectAll(".bar-label")
                .data(d => subgroups.filter(sg => d[sg] !== undefined).map(key => ({ key: key, value: d[key] })))
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScaleSubgroups(d.key) + xScaleSubgroups.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 4).attr("text-anchor", "middle")
                .style("font-size", "9px").style("fill", "var(--sobi-dark-text)")
                .text(d => d.value === NR_Placeholder_Months ? "NR" : `${d.value.toFixed(1)}m`);
            
            svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 - 10) 
                .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)").text(chartTitle);
            
            // Adding text for "Pts in CR at 2y" data as it's a rate
             svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top -15) // Position it below the main title
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("font-style", "italic")
                .style("fill", "var(--sobi-dark-text)")
                .text("Pts in CR at 2y (n=32): 97% OS & 96% PFS at 36 months");


            const legendData = subgroups.map(key => ({ label: displayLabels[key], color: color(key) }));
            const legendItems = legendContainer.selectAll(".legend-item").data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawSurvivalChart = debounce(() => drawEpcorSurvivalChart("#epcorSurvivalChart", "#epcorSurvivalLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawSurvivalChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawSurvivalChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawSurvivalChart, 0); 
        }
    </script>
</body>
</html>
